|
Cortes et al. (2011) [13]
|
III
|
Eribulin mesylate vs TPC
|
508 vs 254
|
13.1
|
3.7
|
3.9
|
13
|
[6]
|
|
Kaufman et al. (2012) [10]
|
III
|
Eribulin mesylate vs Capecitabine
|
554 vs 548
|
15.9
|
4.2
|
4.1
|
11
|
[10]
|
|
Ramaswami et al. (2014) [16]
|
IV
|
Eribulin mesylate
|
25
|
5.89
|
4.08
|
-
|
16
|
[16]
|
|
Poletti et al. (2014) [17]
|
IV
|
Eribulin mesylate
|
27
|
8
|
-
|
2.5
|
9
|
[17]
|
|
Gamucci et al. (2014) [18]
|
IV
|
Eribulin mesylate
|
133
|
14.3
|
4.4
|
5.2
|
21.1
|
[18]
|
|
Rasmussen et al. (2014) [19]
|
IV
|
Eribulin mesylate
|
44
|
-
|
-
|
-
|
12.5
|
[19]
|
|
Present study
|
IV
|
Eribulin mesylate
|
258
|
11.2
|
3.8
|
4.4
|
26
| |
